Immunocytochemical Validation of Hypothalamic Oestrogenic Gnrh Activation Localized in the Arcuate Nucleus of Sheep

Authors: Mguel Merchan Jr., J. Nieto, Javier Plaza, José A. Abecia, Carlos Palacios

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Authors: Rudin, CM, Pandha, HS, Zibelman, M, Akerley, WL, Harrington, KJ, Day, D, Hill, AG, O'Day, SJ, Clay, TD, Wright, GM, Jennens, RR, Gerber, DE, Rosenberg, JE, Ralph, C, Campbell, DC, Curti, BD, Merchan, JR, Ren, Y, Schmidt, EV, Guttman, L, Gupta, S

File Description: text

Relation: https://eprints.whiterose.ac.uk/id/eprint/196781/1/Phase%201,%20open-label,%20dose-escalation%20study%20on%20the%20safety,%20pharmacokinetics,%20and%20preliminary%20efficacy%20of%20intravenous%20Coxsacki.pdf; Rudin, CM, Pandha, HS, Zibelman, M et al. (18 more authors) (2023) Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 11 (1). e005007. ISSN: 2051-1426

Availability: https://eprints.whiterose.ac.uk/id/eprint/196781/

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Authors: Motzer, RJ, Author, Hutson, TE, Author, Cella, D, Author, Reeves, J, Author, Hawkins, R, Author, Guo, J, Author, Nathan, P, Author, Staehler, M, Author, de, Souza P, Author, Merchan, JR, Author

Contributors: Motzer, RJ, Author, Hutson, TE, Author, Cella, D, Author, Reeves, J, Author, Hawkins, R, Author, Guo, J, Author, Nathan, P, Author, Staehler, M, Author, de, Souza P, Author, Merchan, JR, Author

Source: NEW ENGLAND JOURNAL OF MEDICINE. 369(8):722-731

Access URL: https://ki.se/en/research/search-research-information?t=2&query=id%3A527427

Densitometric Analysis of Gnrh and Iba1 Immunocytochemistry in the Basal Ventromedial Hypothalamus of the Ewe

Authors: Merchan Jr., Mguel, Plaza, I, Nieto, J., Plaza, Javier, Abecia, José A., Palacios, Carlos

Availability: http://dx.doi.org/10.2139/ssrn.4770216

Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors.

Authors: Merchan JR; University of Miami, Miami, Florida., Patel MR; University of Minnesota , Minneapolis, Minnesota., Cripe TP; Nationwide Children's Hospital , Columbus, Ohio., Old MO; Ohio State University, Columbus, Ohio., Boughton J; Vyriad, Rochester, Minnesota., Diaz RM; Vyriad, Rochester, Minnesota., Peng KW; Vyriad, Rochester, Minnesota.; Mayo Clinic , Rochester, Minnesota., Russell SJ; Vyriad, Rochester, Minnesota.; Mayo Clinic , Rochester, Minnesota., Russell L; Vyriad, Rochester, Minnesota., Packiriswamy N; Vyriad, Rochester, Minnesota., Wiegert E; Bexon Clinical Consulting LLC, Montclair, New Jersey., Bexon AS; Bexon Clinical Consulting LLC, Montclair, New Jersey., Powell SF; Sanford Health, Sioux Falls, South Dakota.

Source: Cancer research communications [Cancer Res Commun] 2026 Aug 01; Vol. 6 (8), pp. 1862-1874.

Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Neoplasms*/therapy , Neoplasms*/pathology , Neoplasms*/immunology , Oncolytic Viruses*/genetics , Oncolytic Virotherapy*/methods , Oncolytic Virotherapy*/adverse effects , Neoplasm Recurrence, Local*/therapy , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Combined Modality Therapy

Pharmacologic reprogramming of virus-tumor crosstalk enhances measles virus antitumor activity in BRAF mutant colorectal cancer models.

Authors: Chavez V; Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Montero M; Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Tran NHG; Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Mendes CM; University of Miami College of Arts and Sciences, Miami, FL, USA., Ban Y; Department of Public Health Sciences, Division of Biostatistics, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Khurana R; Department of Public Health Sciences, Division of Biostatistics, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Ceccarelli M; Department of Public Health Sciences, Division of Biostatistics, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Merchan JR; Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA. Jmerchan2@med.miami.edu.

Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2026 Jun 06; Vol. 45 (1). Date of Electronic Publication: 2026 Jun 06.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE

MeSH Terms: Measles virus*/physiology , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/therapy , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/virology , Oncolytic Virotherapy*/methods , Proto-Oncogene Proteins B-raf*/genetics , Diterpenes*/pharmacology , Diterpenes*/therapeutic use , Phenanthrenes*/pharmacology , Phenanthrenes*/therapeutic use, Epoxy Compounds/pharmacology ; Epoxy Compounds/therapeutic use ; Humans ; Animals ; Mice ; Xenograft Model Antitumor Assays ; Mutation ; Cell Line, Tumor ; Oncolytic Viruses

EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.

Authors: Rosenberg JE; Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: rosenbj1@mskcc.org., O'Donnell PH; University of Chicago, Chicago, USA., Petrylak DP; Yale Cancer Center, New Haven, USA., Flaig TW; Division of Medical Oncology, CU School of Medicine, Aurora, USA., Hoimes CJ; Duke Cancer Institute, Durham, USA., Gupta S; Cleveland Clinic Taussig Cancer Institute, Cleveland, USA., Mar N; University of California Irvine, Irvine, USA., Friedlander TW; University of California San Francisco Medical Center, San Francisco, USA., Tagawa ST; Weill Cornell Medical Center, New York, USA., Bilen MA; Winship Cancer Institute of Emory University, Atlanta, USA., Brown JR; University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, USA., McKay RR; University of California San Diego, San Diego, USA., Merchan JR; University of Miami, Miami, USA., Srinivas S; Stanford University Medical Center, Stanford, USA., Gorla S; Astellas Pharma, Inc., Northbrook, USA., Moreno BH; Merck & Co., Inc., Rahway, USA., Davis G; Pfizer Inc., Bothell, USA., Wirtz HS; Pfizer Inc., Bothell, USA., Zhu Y; Pfizer Inc., Bothell, USA., Milowsky MI; University of North Carolina, Chapel Hill, USA.

Source: ESMO open [ESMO Open] 2026 Jun; Vol. 11 (6), pp. 107700. Date of Electronic Publication: 2026 May 19.

Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/pharmacology , Antibodies, Monoclonal, Humanized*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/therapeutic use , Carcinoma, Transitional Cell*/drug therapy , Urologic Neoplasms*/drug therapy , Urologic Neoplasms*/pathology , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology, Humans ; Female ; Male ; Follow-Up Studies ; Aged ; Middle Aged ; Aged, 80 and over

Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker Investigation.

Authors: Abdshah A; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Alyamani M; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Burgess RA; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Parekh DJ; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Spieler B; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA., Singal R; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Abramowitz MC; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA., Merchan JR; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Medicine, Medical Oncology Division, University of Miami Miller School of Medicine, Miami, Florida, USA., Pannunzio L; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Mahal BA; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA., Kobetz E; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA., Punnen S; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Bilusic M; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Sharifi N; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.

Source: The Prostate [Prostate] 2026 May; Vol. 86 (7), pp. 771-783. Date of Electronic Publication: 2026 Feb 23.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0045 (Electronic) Linking ISSN: 02704137 NLM ISO Abbreviation: Prostate Subsets: MEDLINE

MeSH Terms: Saliva*/metabolism , Saliva*/chemistry , Metabolomics*/methods , Prostatic Neoplasms*/metabolism , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/blood , Biomarkers, Tumor*/blood , Biomarkers, Tumor*/metabolism, Biomarkers/blood ; Biomarkers/metabolism ; Androgen Antagonists/therapeutic use ; Hydrocortisone/metabolism ; Humans ; Male ; Pilot Projects ; Aged ; Middle Aged ; Community-Based Participatory Research

Oncolytic Virotherapy for Solid Tumors: Clinical Advances and Future Directions.

Authors: Asawa P; Department of Medicine, Miller School of Medicine, Jackson Memorial Hospital, University of Miami, 1600 NW 10th Avenue, Miami, FL 33136, USA., Zheng X; Department of Medicine, Miller School of Medicine, Jackson Memorial Hospital, University of Miami, 1600 NW 10th Avenue, Miami, FL 33136, USA., Merchan JR; Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Avenue, Miami, FL 33136, USA. Electronic address: JMerchan2@med.miami.edu.

Source: Surgical oncology clinics of North America [Surg Oncol Clin N Am] 2026 Apr; Vol. 35 (2), pp. 385-398. Date of Electronic Publication: 2026 Jan 14.

Publication Type: Journal Article; Review

Journal Info: Publisher: Saunders Country of Publication: United States NLM ID: 9211789 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-5042 (Electronic) Linking ISSN: 10553207 NLM ISO Abbreviation: Surg Oncol Clin N Am Subsets: MEDLINE

MeSH Terms: Oncolytic Virotherapy*/methods , Oncolytic Virotherapy*/trends , Neoplasms*/therapy , Neoplasms*/immunology , Oncolytic Viruses*/genetics, Humans ; Animals

A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects.

Authors: Merchan JR; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA. Electronic address: jmerchan2@med.miami.edu., Rodon J; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Venkat S; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA., Donahue A; Sarah Cannon Research Institute at Health ONE, Denver, CO 80218, USA., Thomassen A; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA., Accomando WP; Tocagen Inc., San Diego, CA 92121, USA., Rodriguez-Aguirre M; Tocagen Inc., San Diego, CA 92121, USA., Kwon D; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA., Bentley C; Tocagen Inc., San Diego, CA 92121, USA., Hogan DJ; Tocagen Inc., San Diego, CA 92121, USA., Rodrigues OR; Tocagen Inc., San Diego, CA 92121, USA., Yavrom S; Tocagen Inc., San Diego, CA 92121, USA., Ostertag D; Tocagen Inc., San Diego, CA 92121, USA., Shorr J; Tocagen Inc., San Diego, CA 92121, USA., Falchook GS; Sarah Cannon Research Institute at Health ONE, Denver, CO 80218, USA.

Source: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2025 Nov 05; Vol. 33 (11), pp. 5505-5515. Date of Electronic Publication: 2025 Aug 21.

Publication Type: Journal Article; Clinical Trial, Phase I; Research Support, N.I.H., Extramural

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE

MeSH Terms: Neoplasms*/therapy , Neoplasms*/immunology , Neoplasms*/pathology , Neoplasms*/genetics , Genetic Vectors*/administration & dosage , Genetic Vectors*/genetics , Genetic Vectors*/adverse effects , Cytosine Deaminase*/genetics , Retroviridae*/genetics , Genetic Therapy*/methods, Flucytosine/metabolism ; Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Tumor Microenvironment ; Treatment Outcome ; Immunomodulation

Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.

Authors: Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: motzerr@mskcc.org., Porta C; Interdisciplinary Department of Medicine, University of Bari 'A. Moro' and Division of Medical Oncology, Policlinico Consorziale di Bari, Bari, Italy., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Hutson TE; Texas Tech University Health Science Center, Lubbock, USA., Rha SY; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Merchan JR; University of Miami Sylvester Comprehensive Cancer Center, Miami, USA., Winquist E; Department of Oncology, Western University, London, Ontario, Canada., Gurney H; Department of Medical Oncology, Macquarie University, Sydney, New South Wales, Australia., Grünwald V; Interdisciplinary Genitourinary Oncology, Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany., George S; Roswell Park Cancer Institute, Buffalo, USA., Markensohn J; Merck & Co., Inc., Rahway, USA., Burgents JE; Merck & Co., Inc., Rahway, USA., Cristescu R; Merck & Co., Inc., Rahway, USA., Sachdev P; Eisai Inc., Nutley, USA., Narita Y; Eisai Co., Ltd., Ibaraki, Japan., Huang J; Eisai Inc., Nutley, USA., Zhao Z; Eisai Inc., Nutley, USA., Okpara CE; Eisai Ltd., Hatfield, UK., Minoshima Y; Eisai Co., Ltd., Ibaraki, Japan., Choueiri TK; Dana-Farber Cancer Institute, Boston, USA.

Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2025 Apr; Vol. 36 (4), pp. 375-386. Date of Electronic Publication: 2024 Dec 11.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Comparative Study

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

MeSH Terms: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/genetics , Carcinoma, Renal Cell*/pathology , Carcinoma, Renal Cell*/mortality , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/genetics , Kidney Neoplasms*/pathology , Kidney Neoplasms*/mortality , Biomarkers, Tumor*/genetics , Biomarkers, Tumor*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Sunitinib/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Phenylurea Compounds/administration & dosage ; Quinolines/administration & dosage ; B7-H1 Antigen/metabolism ; B7-H1 Antigen/genetics ; Humans ; Female ; Male ; Middle Aged ; Aged ; Progression-Free Survival ; Adult

Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.

Authors: Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu., Merchan JR; University of Miami Health System, Miami, FL, USA., Figlin R; Cedars-Sinai Medical Center, Los Angeles, CA, USA., McDermott DF; Beth Israel Deaconess Medical Center, Boston, MA, USA., Arrowsmith E; Tennessee Oncology, Chattanooga, TN, USA., Michaelson MD; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Tykodi SS; University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA., Heath EI; Karmanos Cancer Institute, Detroit, MI, USA., Spigel DR; Sarah Cannon Research Institute, Nashville, TN, USA., D'Souza A; Genitourinary Medical Oncology, University of Southern California, Los Angeles, CA, USA., Kassalow L; Merck & Co, Inc, Rahway, NJ, USA., Perini RF; Merck & Co, Inc, Rahway, NJ, USA., Vickery D; Merck & Co, Inc, Rahway, NJ, USA., Bauer TM; Tennessee Oncology/Greco-Hainsworth Centers for Research, Nashville, TN, USA.

Source: The Lancet. Oncology [Lancet Oncol] 2025 Jan; Vol. 26 (1), pp. 64-73.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

MeSH Terms: Anilides*/therapeutic use , Anilides*/administration & dosage , Anilides*/adverse effects , Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/pathology , Pyridines*/administration & dosage , Pyridines*/therapeutic use , Pyridines*/adverse effects , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult

A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.

Authors: Hoimes CJ; Duke Cancer Institute; Duke University, Durham, NC, USA., Flaig TW; University of Colorado Comprehensive Cancer Center, Aurora, CO, USA., Milowsky MI; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Friedlander TW; University of California San Francisco Medical Center, San Francisco, CA, USA., Bilen MA; Winship Cancer Institute of Emory University, Hematology & Medical Oncology, Atlanta, GA, USA., Gupta S; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Srinivas S; Stanford University Medical Center, Stanford, CA, USA., Merchan JR; University of Miami, Medical Oncology, Miami, FL, USA., McKay RR; University of California San Diego Moores Cancer Center, San Diego, CA, USA., Petrylak DP; Yale Comprehensive Cancer Center, New Haven, CT, USA., Sasse C; Astellas Pharma Global Development, Northbrook, IL, USA., Moreno BH; Merck & Co., Inc., Rahway, NJ, USA., Yu Y; Seagen Inc., Bothell, WA, USA., Carret AS; Seagen Inc., Bothell, WA, USA., Rosenberg JE; Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, NY, USA.

Source: Future oncology (London, England) [Future Oncol] 2024 Mar; Vol. 20 (7), pp. 351-360. Date of Electronic Publication: 2023 Nov 23.

Publication Type: Patient Education Handout

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

MeSH Terms: Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/pathology , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology , Urologic Neoplasms*/drug therapy , Urologic Neoplasms*/pathology, Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Humans

Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.

Authors: Jonasch E; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ejonasch@mdanderson.org., Bauer TM; Tennessee Oncology, Nashville, TN, USA., Papadopoulos KP; South Texas Accelerated Research Therapeutics (START), San Antonio, TX, USA., Plimack ER; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA., Merchan JR; University of Miami Health System, Miami, FL, USA., McDermott DF; Beth Israel Deaconess Medical Center, Boston, MA, USA., Dror Michaelson M; Massachusetts General Hospital, Boston, MA, USA., Appleman LJ; University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Roy A; Merck & Co., Inc., Rahway, NJ, USA., Perini RF; Merck & Co., Inc., Rahway, NJ, USA., Liu Y; Merck & Co., Inc., Rahway, NJ, USA., Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Jan; Vol. 196, pp. 113434. Date of Electronic Publication: 2023 Nov 15.

Publication Type: Clinical Trial, Phase I; Journal Article

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

MeSH Terms: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology, Basic Helix-Loop-Helix Proteins/therapeutic use ; Humans ; Follow-Up Studies ; Indenes

Correction: AI-Assisted chemical probe discovery for the understudied Calcium-Calmodulin Dependent Kinase, PNCK.

Authors: Essegian DJ, Chavez V, Khurshid R, Merchan JR, Schürer SC

Source: PLoS computational biology [PLoS Comput Biol] 2023 Nov 22; Vol. 19 (11), pp. e1011672. Date of Electronic Publication: 2023 Nov 22 (Print Publication: 2023).

Publication Type: Published Erratum

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238922 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7358 (Electronic) Linking ISSN: 1553734X NLM ISO Abbreviation: PLoS Comput Biol Subsets: MEDLINE; PubMed not MEDLINE

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.

Authors: Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., George S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Merchan JR; Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA., Hutson TE; Department of Medical Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA., Song X; Clinical Research, Merck & Co., Inc., Rahway, NJ, USA., Perini RF; Clinical Research, Merck & Co., Inc., Rahway, NJ, USA., Xie R; Biostatistics, Eisai Inc., Nutley, NJ, USA., Bapat U; Clinical Research, Eisai Inc., Nutley, NJ, USA., Puente J; Department of Medical Oncology, Hospital Clinico Universitario San Carlos, Madrid, Spain.

Source: The oncologist [Oncologist] 2023 Jun 02; Vol. 28 (6), pp. 501-509.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

MeSH Terms: Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/pathology , Hypertension*/chemically induced , Hypertension*/drug therapy, Phenylurea Compounds/adverse effects ; Fatigue/chemically induced ; Diarrhea/chemically induced ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Antibodies, Monoclonal, Humanized ; Quinolines

AI-Assisted chemical probe discovery for the understudied Calcium-Calmodulin Dependent Kinase, PNCK.

Authors: Essegian DJ; Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, United States of America., Chavez V; Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, United States of America., Khurshid R; Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, United States of America., Merchan JR; Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, United States of America., Schürer SC; Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, United States of America.; Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, United States of America.

Source: PLoS computational biology [PLoS Comput Biol] 2023 May 26; Vol. 19 (5), pp. e1010263. Date of Electronic Publication: 2023 May 26 (Print Publication: 2023).

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238922 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7358 (Electronic) Linking ISSN: 1553734X NLM ISO Abbreviation: PLoS Comput Biol Subsets: MEDLINE

MeSH Terms: Calcium* , Calmodulin*, Artificial Intelligence

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.

Authors: Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy., Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic., Basappa NS; Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Méndez-Vidal MJ; Department of Medical Oncology, Hospital Universitario Reina Sofía, Maimonides Institute for Biomedical Research of Córdoba, Córdoba, Spain., Tjulandin S; Department of Clinical Pharmacology and Chemotherapy, N N Blokhin National Medical Research Center for Oncology, Ministry of Health of the Russian Federation, Moscow, Russia., Hoon Park S; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Melichar B; Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Hutson T; Department of Medical Oncology, Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX, USA., Alemany C; Department of Hematology and Oncology, AdventHealth Cancer Institute, Orlando, FL, USA., McGregor B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Powles T; Department of Oncology, The Royal Free NHS Trust, London, England, UK; Department of Oncology, Barts Cancer Institute, Queen Mary Institute of London, London, UK., Grünwald V; Clinic for Urology and Clinic for Medical Oncology, University Hospital Essen, Essen, Germany., Alekseev B; Department of Onco-urology, P A Hertsen Moscow Cancer Research Institute, Moscow, Russia., Rha SY; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Kopyltsov E; State Institution of Healthcare 'Regional Clinical Oncology Dispensary', Omsk, Russia., Kapoor A; Division of Urology, Department of Surgery, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada., Alonso Gordoa T; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Goh JC; ICON Research, South Brisbane, QLD, Australia; Department of BioMedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia., Staehler M; Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany., Merchan JR; Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA., Xie R; Biostatistics, Eisai, Nutley, NJ, USA., Perini RF; Clinical Research, Merck, Rahway, NJ, USA., Mody K; Clinical Research, Eisai, Nutley, NJ, USA., McKenzie J; Clinical Research, Eisai, Nutley, NJ, USA., Porta CG; Interdisciplinary Department of Medicine, University of Bari 'A Moro', Bari, Italy.

Source: The Lancet. Oncology [Lancet Oncol] 2023 Mar; Vol. 24 (3), pp. 228-238.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

MeSH Terms: Carcinoma, Renal Cell* , Kidney Neoplasms*, Female ; Humans ; Male ; Middle Aged ; Everolimus ; Follow-Up Studies ; Sunitinib ; Phenylurea Compounds ; Quinolines ; Antibodies, Monoclonal, Humanized

Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets.

Authors: Tan SK; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.; Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL, USA., Hougen HY; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA., Merchan JR; Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Gonzalgo ML; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Welford SM; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA. Scott.welford@med.miami.edu.; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. Scott.welford@med.miami.edu.

Source: Nature reviews. Urology [Nat Rev Urol] 2023 Jan; Vol. 20 (1), pp. 48-60. Date of Electronic Publication: 2022 Oct 03.

Publication Type: Journal Article; Review; Research Support, N.I.H., Extramural

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500082 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-4820 (Electronic) Linking ISSN: 17594812 NLM ISO Abbreviation: Nat Rev Urol Subsets: MEDLINE

MeSH Terms: Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/pathology, Lipid Metabolism/genetics ; Fatty Acids/metabolism ; Humans ; Lipids

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.

Authors: Rudin CM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA rudinc@mskcc.org.; Professor of Medicine, Weill Cornell Medical College, New York, New York, USA., Pandha HS; University of Surrey, Guildford, UK., Zibelman M; Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Akerley WL; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Harrington KJ; The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, London, UK., Day D; Department of Oncology, Monash Health and Monash University, Clayton, Victoria, Australia., Hill AG; Tasman Oncology Research Ltd, Southport, Queensland, Australia., O'Day SJ; John Wayne Cancer Institute, Providence St John's Health Center, Santa Monica, California, USA., Clay TD; Medical Oncology, St. John of God Subiaco Hospital, Perth, Western Australia, Australia., Wright GM; Department of Surgery, St Vincent's Hospital Melbourne, The University of Melbourne, Fitzroy, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia., Jennens RR; Epworth Healthcare, Richmond, Victoria, Australia., Gerber DE; Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Rosenberg JE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Ralph C; Division of Medical Oncology, Institute of Oncology, St. James's University Hospital, Leeds, UK., Campbell DC; Western Health, Sunshine Hospital, St Albans, Victoria, Australia., Curti BD; Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, Oregon, USA., Merchan JR; University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, Florida, USA., Ren Y; Merck & Co., Inc, Rahway, New Jersey, USA., Schmidt EV; Merck & Co., Inc, Rahway, New Jersey, USA., Guttman L; Practical Clinical, Mississauga, Ontario, Canada., Gupta S; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jan; Vol. 11 (1).

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

MeSH Terms: Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy , Oncolytic Viruses*, Antibodies, Monoclonal, Humanized/adverse effects ; Male ; Humans